Antengene to Present Latest Preclinical Results of ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at ACR 2026

ConferenceATG-207Neutral

AI Analysis

Summary

Antengene announced it will present preclinical results of ATG-207, an αCD3-TGF-β bifunctional fusion protein, at ACR 2026. This is a routine conference presentation announcement with early-stage preclinical data.

Clinical Trial Data

Phase

preclinical

Importance:3/10

Sentiment:

0.00

preclinicalconference presentationACR 2026bifunctional fusion protein

Related Companies

$GBCMD $TRAX

Read the original article

Published by PR Newswire Pharma on October 9, 2026 2:48 AM

Read Original